IFACT: Incidental Findings in Advanced Cancer Therapy

Part 1, the investigators will recruit 40 participants from those already enrolled in
existing MSK IRB protocol #12-245 (PI: David Hyman, MD) including male and female patients
who have been diagnosed with late-stage breast, colorectal, bladder, and lung cancer (some
of the most common cancers in this study population).

Part 2, the investigators will recruit 20 participants from those who have actually received
incidental germline findings from MSK IRB protocol #12-245 Consent Part C in order to
cognitively test novel survey items about their knowledge and perceived utility of their
incidental findings (note that the content of these items will be derived from the data
collected in Part 1)

Inclusion Criteria:

Part 1:

- Patient enrolled on MSK protocol #12-245

- Living patient age 18 or older

- Patient diagnosed with breast cancer, colorectal cancer, bladder cancer, or lung
cancer

- Patient residing in New York metro-area

Part 2:

- Living patient age 18 or older

- Consented to Part C of IRB#12-245 and has received results regardless if thereir was
a pathogenic variant

- Patient diagnosed with cancer type approved for IRB#12-245 Part C (which are
currently breast cancer, gynecological cancer, prostate cancer, and GU non-prostate
cancer)breast cancer, colorectal cancer, bladder cancer, or lung cancer

- Patient residing in New York metro-area

Exclusion Criteria for Part 1 and 2:

- Non-English speakers because we do not have the resources to conduct and translate
the interviews into other languages.

- Patient unwilling or unable to provide informed consent.